Funding for NIH Research, Center for Disease Control and Prevention, Health Resources and Service Administration, Substance Abuse and Mental Health Administration, Ryan White HIV/AIDS Program, PEPFAR and Global Fund, Minority AIDS Initiative, 21st Century CURES Act
Issues related to HIV/AIDS, expanded access to HIV prevention and treatment services, syringe services programs, issues related to the opioid epidemic, hepatitis C, Medication-Assisted Treatment, substance abuse treatment facilities and access to care
Issues related to President's Plan for AIDS Relief (PEPFAR), Global Fund and global health programs
Issues related to hepatitis C testing and reporting, HIV research, NIH research
Duration: November 1, 2007
to
June 30, 2009
General Issues: Budget/Appropriations , Health Issues , Foreign Relations , Medical/Disease Research/Clinical Labs , Housing , Alcohol & Drug Abuse , Medicare/Medicaid , District of Columbia
Spending: about $2,840,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Substance Abuse & Mental Health Services Administration (SAMHSA), Office of Natl Drug Control Policy (NDCP), State - Dept of (DOS), Natl Institutes of Health (NIH), Health & Human Services - Dept of (HHS), Y
Y
Department of Health and Human Services - NIH, CDC, Y
Y
Department of State - Office of Global AIDS Coordinator, Y
Y, Y
Y
Department of State - Office of AIDS Coordinator
Department of Health and Human Services - NIH
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on April 22.
Original Filing: 301576109.xml
4th Quarter, 2023
In Q4, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on Jan. 22.
Original Filing: 301540207.xml
3rd Quarter, 2023
In Q3, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on Oct. 20, 2023.
Original Filing: 301516357.xml
2nd Quarter, 2023
In Q2, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on July 20, 2023.
Original Filing: 301485451.xml
1st Quarter, 2023
In Q1, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on April 20, 2023.
Original Filing: 301466446.xml
4th Quarter, 2022
In Q4, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on Jan. 20, 2023.
Original Filing: 301440352.xml
3rd Quarter, 2022
In Q3, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on Oct. 20, 2022.
Original Filing: 301417568.xml
2nd Quarter, 2022
In Q2, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on July 20, 2022.
Original Filing: 301394800.xml
1st Quarter, 2022
In Q1, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on April 22, 2022.
Original Filing: 301373253.xml
4th Quarter, 2021
In Q4, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on Jan. 20, 2022.
Original Filing: 301336036.xml
3rd Quarter, 2021
In Q3, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on Oct. 20, 2021.
Original Filing: 301312238.xml
2nd Quarter, 2021
In Q2, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on July 20, 2021.
Original Filing: 301290395.xml
1st Quarter, 2021
In Q1, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on April 21, 2021.
Original Filing: 301268482.xml
4th Quarter, 2020
In Q4, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on Jan. 21, 2021.
Original Filing: 301245286.xml
3rd Quarter, 2020
In Q3, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on Oct. 20, 2020.
Original Filing: 301224112.xml
2nd Quarter, 2020
In Q2, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on July 20, 2020.
Original Filing: 301200545.xml
1st Quarter, 2020
In Q1, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on April 20, 2020.
Original Filing: 301177359.xml
4th Quarter, 2019
In Q4, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on Jan. 17, 2020.
Original Filing: 301108381.xml
3rd Quarter, 2019
In Q3, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on Oct. 22, 2019.
Original Filing: 301079654.xml
2nd Quarter, 2019
In Q2, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on July 22, 2019.
Original Filing: 301055871.xml
Lobbying Issues
Funding for NIH Research, Center for Disease Control and Prevention, Health Resources and Service Administration, Substance Abuse and Mental Health Administration, Ryan White HIV/AIDS Program, PEPFAR and Global Fund, Minority AIDS Initiative, 21st Century CURES Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to HIV/AIDS, expanded access to HIV prevention and treatment services, syringe services programs, issues related to the opioid epidemic, hepatitis C, Medication-Assisted Treatment, substance abuse treatment facilities and access to care
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to President's Plan for AIDS Relief (PEPFAR), Global Fund and global health programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to hepatitis C testing and reporting, HIV research, NIH research
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2019
In Q1, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on April 17, 2019.
Original Filing: 301027226.xml
Lobbying Issues
Funding related to HIV/AIDS, the opioid epidemic, hepatitis, funding for NIH Research, Center for Disease Control and Prevention (CDC), Health Resources Service Administration (HRSA), Substance Abuse and Mental Health Service Administration (SAMHSA), Ryan White HIV/AIDS Program, Minority AIDS Initiative, President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to HIV/AIDS, the opioid epidemic, expanded access to HIV prevention and treatment services, syringe exchange programs, hepatitis C, access to Medication-Assisted Treatment and substance use treatment facilities
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Housing Opportunities for Persons with HIV/AIDS (HOPWA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to President's Plan for AIDS Relief (PEPFAR), Global Fund and global health programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to hepatitis C testing and reporting, HIV research, NIH research
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the opioid epidemic, treatment services for substance use disorder
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicaid and Medicare coverage as it affects people living with HIV/AIDS, and as it relates to the opioid epidemic and substance use treatment
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on Jan. 23, 2019.
Original Filing: 301018395.xml
Lobbying Issues
Funding related to HIV/AIDS, the opioid epidemic,hepatitis; funding for NIH Research, Center for Disease Control and Prevention,Health Resources Service Administration (HRSA), Substance Abuse and Mental Health Service Administration (SAMHSA), Ryan White HIV/AIDS Program, Minority AIDS Initiative, President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the opioid epidemic, HIV/AIDS, expanded access to HIV prevention and treatment services, syringe exchange programs, hepatitis C, access to Medication-Assisted Treatment and substance abuse treatment facilities
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Housing Opportunities for Persons with HIV/AIDS (HOPWA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to hepatitis C testing and reporting, HIV research, NIH research
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
issues related to the opioid epidemic and treatment services for substance abuse
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicaid and Medicare coverage as it affects people living with HIV/AIDS, and as it relates to the opioid epidemic and substance use treatment
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on Oct. 23, 2018.
Original Filing: 300998978.xml
Lobbying Issues
Funding related to HIV/AIDS, the opioid epidemic,hepatitis; funding for NIH Research, Center for Disease Control and Prevention,Health Resources Service Administration (HRSA), Substance Abuse and Mental Health Service Administration (SAMHSA), Ryan White HIV/AIDS Program, Minority AIDS Initiative, President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the opioid epidemic, HIV/AIDS, expanded access to HIV prevention and treatment services, syringe exchange programs, hepatitis C, access to Medication-Assisted Treatment and substance abuse treatment facilities
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Housing Opportunities for Persons with HIV/AIDS (HOPWA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to hepatitis C testing and reporting, HIV research, NIH research
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
issues related to the opioid epidemic and treatment services for substance abuse
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicaid and Medicare coverage as it affects people living with HIV/AIDS, and as it relates to the opioid epidemic and substance use treatment
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on July 19, 2018.
Original Filing: 300969748.xml
Lobbying Issues
Funding related to HIV/AIDS, the opioid epidemic,hepatitis; funding for NIH Research, Center for Disease Control and Prevention,Health Resources Service Administration (HRSA), Substance Abuse and Mental Health Service Administration (SAMHSA), Ryan White HIV/AIDS Program, Minority AIDS Initiative, President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the opioid epidemic, HIV/AIDS, expanded access to HIV prevention and treatment services, syringe exchange programs, hepatitis C, access to Medication-Assisted Treatment and substance abuse facilities
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Housing Opportunities for Persons with HIV/AIDS (HOPWA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to hepatitis C testing and reporting, HIV research, NIH research
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
issues related to the opioid epidemic and treatment services for substance abuse
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicaid and Medicare coverage as it affects people living with HIV/AIDS, and as it relates to the opioid epidemic and substance use treatment
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on April 23, 2018.
Original Filing: 300958861.xml
Lobbying Issues
Funding related to HIV/AIDS, the opioid epidemic, and hepatitis; funding for NIH Research, Center for Disease Control and Prevention, Fogarty International, Health Resources Service Administration (HRSA), Substance Abuse and Mental Health Service Administration (SAMHSA), Ryan White HIV/AIDS Program, Minority AIDS Initiative, President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the opioid epidemic, HIV/AIDS, expanded access to HIV prevention and treatment services, syringe exchange programs, hepatitis C, and access to care and Medication-Assisted Treatment.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Housing Opportunities for Persons with HIV/AIDS (HOPWA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs, Protecting Life in Global Health Assistance Policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to hepatitis C testing and reporting, HIV research, NIH research
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
issues related to the opioid epidemic and treatment services for substance use disorder
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicaid and Medicare coverage as it affects people living with HIV/AIDS, and as it relates to the opioid epidemic and substance use treatment
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on Jan. 25, 2018.
Original Filing: 300938541.xml
Lobbying Issues
Funding related to HIV/AIDS, the opioid epidemic, and hepatitis; funding for NIH Research, Center for Disease Control and Prevention, Fogarty International, Health Resources Service Administration (HRSA), Substance Abuse and Mental Health Service Administration (SAMHSA), Ryan White HIV/AIDS Program, Minority AIDS Initiative, President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the opioid epidemic, HIV/AIDS, expanded access to HIV prevention and treatment services, syringe exchange programs, hepatitis C, and access to care.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Housing Opportunities for Persons with HIV/AIDS (HOPWA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs, Protecting Life in Global Health Assistance Policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to hepatitis C testing and reporting, HIV research, NIH research
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
issues related to the opioid epidemic and treatment services for substance misuse
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicaid and Medicare coverage as it affects people living with HIV/AIDS, and as it relates to the opioid epidemic and substance misuse treatment
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on Oct. 19, 2017.
Original Filing: 300909925.xml
Lobbying Issues
Funding related to HIV/AIDS, the opioid epidemic, and hepatitis; funding for NIH Research, Center for Disease Control and Prevention, Fogarty International, Health Resources Service Administration (HRSA), Substance Abuse and Mental Health Service Administration (SAMHSA), Ryan White HIV/AIDS Program, Minority AIDS Initiative, President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to HIV/AIDS, expanded access to HIV prevention and treatment services, syringe exchange programs, issues related to the opioid epidemic, hepatitis C, and access to care
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Housing Opportunities for Persons with HIV/AIDS (HOPWA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to hepatitis C testing and reporting, HIV research, NIH research
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
issues related to the opioid epidemic and treatment services for substance misuse
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicaid and Medicare coverage as it affects people living with HIV/AIDS, and as it relates to the opioid epidemic and substance misuse treatment
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300894825.xml
Lobbying Issues
Funding for NIH Research, Center for Disease Control and Prevention, Fogarty International, Health Resources Service Administration (HRSA), Substance Abuse and Mental Health Service Administration (SAMHSA), Ryan White HIV/AIDS Program, President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to HIV/AIDS; expanded access to HIV prevention and treatment services, syringe exchange programs, issues related to the opioid epidemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Housing Opportunities for Persons with HIV/AIDS (HOPWA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to hepatitis C testing and reporting, HIV research.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2017
amfAR The Foundation for AIDS Research amended a lobbying report for in-house lobbying in Q12017 on July 20, 2017
Original Filing: 300895845.xml
Lobbying Issues
Funding for NIH Research, Center for Disease Control and Prevention, Ryan White HIV/AIDS Program, President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to HIV/AIDS; expanded access to HIV prevention and treatment services, syringe exchange programs, opioid epidemic, HHS Nominee Tom Price.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to HOPWA, Housing Opportunities for Persons with HIV/AIDS, HUD Nominee Ben Carson.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs, Secretary of State Nominee Rex Tillerson.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to hepatitis C testing and reporting.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2017
In Q1, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300877191.xml
Lobbying Issues
Funding for NIH Research, Center for Disease Control and Prevention, Ryan White HIV/AIDS Program, President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to HIV/AIDS; expanded access to HIV prevention and treatment services, syringe exchange programs, opioid epidemic, HHS Nominee Tom Price.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to HOPWA, Housing Opportunities for Persons with HIV/AIDS, HUD Nominee Ben Carson.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund and global health programs, Secretary of State Nominee Rex Tillerson.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to hepatitis C testing and reporting.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2016
In Q4, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on Jan. 24, 2017.
Original Filing: 300858670.xml
Lobbying Issues
Funding for National Institute of Health and President's Emergency Plan for AIDS Relief (PEPFAR).
Agencies Lobbied
U.S. Senate
Lobbying Issues
U.S. Global AIDS Coordinator appointment.
Lobbying Issues
Nomination of Secretary, Health and Human Services;
Issues related to HIV/AIDS;
Expanded access to HIV prevention and treatment services, syringe exchange programs;
World AIDS Day.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for hepatitis C testing.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2016
amfAR The Foundation for AIDS Research filed a lobbying registration on Dec. 1, 2016 for in-house lobbying efforts, effective Oct. 17, 2016.
Original Filing: 300842283.xml
Issue(s) they said they’d lobby about: Appropriations as related to Department of Health and Human Services and Department of State; domestic HIV funding and syringe exchange programs; funding for global HIV programs. .
2nd Quarter, 2009
amfAR The Foundation for AIDS Research in-house lobbying effort was terminated on July 20, 2009
Original Filing: 300191826.xml
1st Quarter, 2009
In Q1, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on April 21, 2009.
Original Filing: 300165841.xml
4th Quarter, 2008
In Q4, amfAR The Foundation for AIDS Research did no lobbying for itself. The report was filed on Jan. 16, 2009.
Original Filing: 300122819.xml
3rd Quarter, 2008
In Q3, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on Oct. 20, 2008.
Original Filing: 300105803.xml
Lobbying Issues
FY2009 Appropriations: Labor/HHS/Education-increased funding for medical research, National Institutes of Health and other Public Health Services, against funding for abstinence-only programs- (Foreign Operations Appropriations)supported language requesting support for regional initiatives such as TREAT Asia Program and Global AIDS Funding
Financial Services Appropriations: General Provision regarding needle exchange
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY2009 Appropriations: Financial Services
General Provision regarding needle exchange
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Global AIDS Issues-especially the epidemic in Asia -S.2731/HR5501-Reauthorization of PEPFAR
-S. 2486 - HIV Nondiscrimination and Travel Act
Domestic AIDS Issues - HIV and Corrections -HR 178 and HR 1943
HR 6680 The Community AIDS and Hepatitis Prevention (CAHP) Act of 2008
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on July 22, 2008.
Original Filing: 300083323.xml
Lobbying Issues
FY2009 Appropriations: Labor/HHS/Education-increased funding for medical research, National Institutes of Health and other Public Health Services, against funding for abstinence-only programs- (Foreign Operations Appropriations)supported language requesting support for regional initiatives such as TREAT Asia Program and Global AIDS Funding
Financial Services Appropriations: General Provision regarding needle exchange
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY2009 Appropriations: Financial Services
General Provision regarding needle exchange
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Global AIDS Issues-especially the epidemic in Asia -S.2731/HR5501-Reauthorization of PEPFAR
-S. 2486 - HIV Nondiscrimination and Travel Act
Domestic AIDS Issues - HIV and Corrections -HR 178 and HR 1943
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, amfAR The Foundation for AIDS Research had in-house lobbyists. The report was filed on April 14, 2008.
Original Filing: 300036100.xml
Lobbying Issues
FY2008 Appropriations: Labor/HHS/Education HR3043-increased funding for medical research, National Institutes of Health and other Public Health Services, against funding for abstinence-only programs-HR2764 (Foreign Operations Appropriations)supported language requesting support for regional initiatives such as TREAT Asia Program and Global AIDS Funding-HR2829(District of Columbia Appropriations) General Provision regarding needle exchange
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY2008 Appropriations: Financial Services
-HR 2829 General Provision regarding needle exchange
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Global AIDS Issues-especially the epidemic in Asia -S.2731/HR5501-Reauthorization of PEPFAR-HR 1713 PATHWAY Act- against the prostitution pledge and abstinence-only programs in Global AIDS Bills -S. 2486 -HIV Nondiscrimination and Travel Act
Domestic AIDS Issues - against support for abstinence-only programs/end federal ban on syringe exchange
-HR 1653 REAL Act to provide for reduction of unintended pregnancy, HIV rates and other STD's
Agencies Lobbied
U.S. House of Representatives
0th Quarter, 2007
In MM, The Foundation for AIDS Research amfAR had in-house lobbyists. The report was filed on July 24, 2007.
Original Filing: 200040916.xml
Lobbying Issues
FY2008 Appropriations:Labor/HHS/Education HR3043 - increased funding for medical research, National Institutes of Health and other Public Health Services, against funding for abstinence-only programs
-HR 1653 REAL Act - to provide for the reduction of unintended pregnancy, HIV rates and other STD's
Agencies Lobbied
Y
Y
Department of Health and Human Services - NIH
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
FY2008 Appropriations: Labor/HHS/Education HR3043- increased funding for medical research, National Institutes of Health and other Public Health Services, against funding for abstinence-only programs - HR2764(Foreign Operations Appropriations) supported language requesting support for regional initiatives such as TREAT Asia Program and Global AIDS Funding -HR2829 (District of Columbia Appropriations) General Provision regarding needle exchange
Agencies Lobbied
Y
Y
Department of State - Office of Global AIDS Coordinator
Lobbying Issues
FY2008 Appropriations: Fnancial Services
-HR 2829 General Provision regarding needle exchange
Lobbying Issues
Global AIDS Issues - particularly the epidemic in Asia
-HR 1713 PATHWAY Act- against the prostitution pledge and abstinence-only programs in Global AIDS Bills
Domestic AIDS Issues - against support for abstinence-only programs
-HR 1653 REAL Act to provide for reduction of unintended pregnacy, HIV rates and other STD's
Agencies Lobbied
Y
Y
Department of State - Office of AIDS Coordinator
Department of Health and Human Services - NIH
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...